care & love
Brazil is one of the largest medical device markets in Latin America, and for good reason. With a public healthcare system that serves more than 200 million people and a fast-growing private hospital sector, the country offers real opportunities for manufacturers and distributors of everything from basic hospital furniture to advanced rehabilitation robotics. But getting products into the hands of Brazilian hospitals and clinics is not a simple matter of finding a local partner and shipping a container. Brazil operates one of the most structured regulatory systems in the region, and every distributor, importer, and wholesaler must work within it.
This guide explains the medical equipment distributor regulations in Brazil, what they mean in practice, and how suppliers can prepare before entering the market.
All medical equipment distribution in Brazil is overseen by ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Surveillance Agency. Created by Law 9,782/1999, ANVISA is responsible for product registration, company authorization, good manufacturing practice certification, border controls, and post-market surveillance. No medical device can be legally sold, imported, or distributed in Brazil without its involvement. The agency also enforces compliance across the entire supply chain, so a distributor that handles unregistered products can face serious penalties, including fines and suspension of its operating license.
One of the most important rules for foreign suppliers to understand is that ANVISA only issues distribution and import licenses to companies established in Brazil. A foreign manufacturer cannot apply for these licenses directly. Instead, it must appoint a local partner, typically an importer or a Brazil Registration Holder (BRH), who acts as the liaison with ANVISA and is named on the product registration. This means choosing the right Brazilian partner is not just a commercial decision; it is a regulatory one. The partner must hold a valid CNPJ number, a local operating license, and the appropriate ANVISA authorizations before any shipment can be cleared.
Every company that imports, distributes, or wholesales medical devices in Brazil must hold an AFE (Autorização de Funcionamento), an operating authorization granted by ANVISA. The AFE is issued per establishment, which means each warehouse or distribution center needs its own authorization. To obtain an AFE, a company must submit an electronic petition with corporate documents, proof of tax and legal regularity, registration of a technically responsible professional, and evidence that its facilities comply with good distribution and storage practices, usually confirmed through a sanitary inspection or a local license from the state or municipal health authority. Because the AFE is tied to a specific site, expanding into a new city or adding a second warehouse means applying for an additional authorization.
Before any device can be distributed, it must be authorized for the market. Under RDC 751/2022, which took effect in March 2023 and replaced the older RDC 185/2001, medical devices are classified into four risk classes (I to IV). Class I and II devices follow a notification pathway that is automatically approved, while Class III and IV devices require a full registration with a technical dossier covering design, manufacturing, risk management, and clinical evidence where needed. Imported Class III and IV devices must also show proof of approval in their country of origin. The classification determines both the paperwork and the timeline, so getting it right at the start saves months of delay.
Many medical devices need more than ANVISA registration. Electrical, electronic, and electromedical equipment must obtain INMETRO certification, which involves electrical safety testing by accredited laboratories in Brazil. Devices with wireless communication, such as Bluetooth, Wi-Fi, or cellular modules, must also obtain ANATEL certification. Both certifications must remain valid for as long as the product is marketed in the country, and their costs and renewal cycles should be included in any market-entry budget.
All labeling and instructions for use must be in Portuguese, and the labeling must comply with ANVISA’s requirements, including the registration number and the details of the responsible company. Distributors are expected to keep records that allow products to be traced from the manufacturer to the end user, so batch numbers and distribution logs should be maintained carefully from the first shipment.
Distribution does not end with the sale. Distributors share responsibility for post-market surveillance, including reporting adverse events and field safety actions to ANVISA. If a product is found to be unsafe, the distributor must cooperate with recalls and corrective actions. These obligations apply to every link in the chain, which is why distributors should only work with manufacturers that can provide complete technical documentation and responsive after-sales support.
For manufacturers of products such as nursing beds, lower limb exoskeletons, and patient lifts, the path into Brazil typically looks like this: first, classify the product under RDC 751/2022; second, appoint a Brazilian importer or BRH with a valid AFE; third, complete the notification or registration with ANVISA; fourth, obtain any required INMETRO and ANATEL certifications; and finally, ensure Portuguese labeling and post-market systems are in place before the first shipment. Each step builds on the previous one, so a clear timeline and a single point of responsibility on the Brazilian side make the process far more manageable.
Brazil’s distributor regulations are demanding, but they are also predictable. By understanding the role of ANVISA, the AFE requirement, the classification system, and the additional certifications, manufacturers and distributors can enter the market with confidence. Working with an experienced local partner is the single most important step, and in Brazil it is a legal requirement, not just a business preference.